Popular Trials
Behavioural Intervention
Electro-acupuncture + TES for Retinitis Pigmentosa
Recruiting0 awards6 criteria
Fort Lauderdale, Florida
This trial is testing a treatment called transcorneal electrical stimulation for people with retinitis pigmentosa, a condition that leads to gradual vision loss. The treatment uses small electrical currents applied to the eye to improve blood flow and stimulate retinal cells, which may help slow down vision loss. Transcorneal electrical stimulation has shown several improvements in visual function in previous studies and is currently offered by several companies.
Stem Cell Therapy
Stem Cells for Retinal Disease
Recruiting1 awardPhase 1
Sacramento, California
This trial is testing if injecting special cells from bone marrow into the eye is safe and possible for patients who are permanently blind due to retinal diseases. The hope is that these cells can help fix the damaged parts of their eyes.
Gene Therapy
Gene Therapy with Light-Stimulating Glasses for Retinitis Pigmentosa
Recruiting1 awardPhase 1 & 2
Pittsburgh, Pennsylvania
This trial is testing a new gene therapy injected into the eye and special light-stimulating glasses for patients with a specific type of vision loss called non-syndromic Retinitis Pigmentosa. The gene therapy aims to fix genetic problems in the eye, while the glasses help activate the treated cells. Gene therapy has shown promise in treating retinal diseases.
Cell Therapy
hRPC for Retinitis Pigmentosa
Recruiting1 awardPhase 1 & 2
Phoenix, Arizona
This trial tests a new cell therapy where special cells are injected into the eye to help people with retinitis pigmentosa, a disease that causes vision loss. The goal is to see if these cells can repair or replace damaged parts of the eye.
Popular Filters
Trials for RP Patients
Gene Therapy
Gene Therapy with SPVN06 for Cone-Rod Dystrophy
Recruiting1 awardPhase 1 & 2
Pittsburgh, Pennsylvania
This trial is testing a new treatment for patients with advanced vision problems caused by specific genetic mutations. The study aims to determine the appropriate dose and evaluate its effectiveness.
Antioxidant
N-acetylcysteine for Retinitis Pigmentosa
Recruiting1 awardPhase 3
Davis, California
This trial is testing if N-acetylcysteine (NAC) can help slow down vision loss in people with Retinitis Pigmentosa (RP). RP is a genetic condition that causes gradual vision loss. NAC reduces damage caused by too much oxygen around eye cells, potentially protecting vision. N-acetylcysteine (NAC) has been shown to reduce oxidative damage and increase cone function/survival in studies related to RP.
Stem Cell Therapy
Stem Cell Implantation for Retinitis Pigmentosa
Recruiting1 awardPhase 1
Beverly Hills, California
This trial is testing if introducing special cells into the eye is safe for patients with vision loss. The cells might help protect and support the existing nerve cells in the eye, potentially slowing down or stopping vision loss.
Virus Therapy
Gene Therapy for Retinitis Pigmentosa
Recruiting1 awardPhase 1 & 2
New York, New York
This trial tests a modified virus that carries a light-sensitive gene to help people with vision problems. The virus delivers this gene to eye cells, making them respond to light and potentially improving vision.
Trials for Retinal Disease Patients
Stem Cell Therapy
Stem Cell Therapy for Retinal and Optic Nerve Disorders
Recruiting1 award8 criteria
Westport, Connecticut
This trial will use stem cells from patients' own bone marrow to treat severe vision loss caused by retinal or optic nerve damage. The stem cells will be injected into the eye to help repair the damaged tissues. SCOTS is the largest ophthalmology stem cell study registered at the National Institutes of Health, using autologous bone marrow-derived stem cells for retinal and optic nerve diseases.
Virus Therapy
VP-001 for Retinal Dystrophy
Recruiting1 awardPhase 1 & 2
Jacksonville, Florida
This trial is testing the safety and effectiveness of a medication called VP-001 in people with a specific type of eye disease called PRPF31 mutation-associated Retinal Dystrophy. Participants will receive different
Phase 3 Trials
Antioxidant
N-acetylcysteine for Retinitis Pigmentosa
Recruiting1 awardPhase 3
Davis, California
This trial is testing if N-acetylcysteine (NAC) can help slow down vision loss in people with Retinitis Pigmentosa (RP). RP is a genetic condition that causes gradual vision loss. NAC reduces damage caused by too much oxygen around eye cells, potentially protecting vision. N-acetylcysteine (NAC) has been shown to reduce oxidative damage and increase cone function/survival in studies related to RP.
Gene Therapy
Gene Therapy for Retinitis Pigmentosa
Recruiting2 awardsPhase 3
Gainesville, Florida
This trial tests a gene therapy for people with X-linked retinitis pigmentosa. It uses a harmless virus to deliver a healthy gene to eye cells, aiming to improve their function and slow down vision loss. Gene therapy targeting the RPE65 gene has shown promise in treating inherited retinal dystrophies, including retinitis pigmentosa.
Gene Therapy
BIIB111 for Choroideremia & BIIB112 for X-Linked Retinitis Pigmentosa
Recruiting2 awardsPhase 3
Gainesville, Florida
This trial will compare the long-term safety and efficacy of a sub-retinal injection of BIIB111 in participants with Choroideremia (CHM) who have been previously treated with BIIB111, with untreated control participants who have exited the STAR (NCT03496012) study. The trial will also compare BIIB112 in participants with X-linked retinitis pigmentosa (XLRP) who have been previously treated with BIIB112.
Trials With No Placebo
Gene Therapy
Gene Therapy with SPVN06 for Cone-Rod Dystrophy
Recruiting1 awardPhase 1 & 2
Pittsburgh, Pennsylvania
This trial is testing a new treatment for patients with advanced vision problems caused by specific genetic mutations. The study aims to determine the appropriate dose and evaluate its effectiveness.
Stem Cell Therapy
Stem Cell Implantation for Retinitis Pigmentosa
Recruiting1 awardPhase 1
Beverly Hills, California
This trial is testing if introducing special cells into the eye is safe for patients with vision loss. The cells might help protect and support the existing nerve cells in the eye, potentially slowing down or stopping vision loss.
Virus Therapy
Gene Therapy for Retinitis Pigmentosa
Recruiting1 awardPhase 1 & 2
New York, New York
This trial tests a modified virus that carries a light-sensitive gene to help people with vision problems. The virus delivers this gene to eye cells, making them respond to light and potentially improving vision.
Antioxidant
N-acetylcysteine for Retinitis Pigmentosa
Recruiting2 awardsPhase 1
Baltimore, Maryland
This trial is testing N-acetylcysteine (NAC) tablets to help people with Retinitis Pigmentosa (RP), a disease that causes vision loss. NAC is an antioxidant that protects eye cells from damage. The goal is to see if NAC can slow down or stop the progression of vision loss in RP patients.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.